Opinion|Videos|October 5, 2023

Expert Perspectives on BOLT clinical trial data

John Strasswimmer, MD, PhD comments on the impressive utility of both vismodegib and sonidegib in patients with advanced basal cell carcinoma and Jonathan S Zager, MD, FACS, FSSO provides his insight into the clinical utility of both of these treatments.

Jonathan S Zager, MD, FACS, FSSO

Moffitt Cancer Center

Tampa, Florida

Lilia Correa-Selm, MD, FAAD, FACMS

Moffitt Cancer Center

Tampa, Florida

Aaron Farberg, MD

Bare Dermatology

Dallas, Texas

John Strasswimmer, MD, PhD

Florida Atlantic University

Delray Beach, Florida

Andrew Weinstein, MD, MPH, FAAD

Boynton Beach Skin, University of Miami

Boynton Beach and Coral Gables, Florida

Series Description: Experts in dermatology discuss the clinical trial data from the BOLT and EVRIANCE clinical trials and review patient cases related to the management of patients with locally advanced basal cell carcinoma treated with sonidegib and vismodegib.

Segment Description: John Strasswimmer, MD, PhD comments on the impressive utility of both vismodegib and sonidegib in patients with advanced basal cell carcinoma and Jonathan S Zager, MD, FACS, FSSO provides his insight into the clinical utility of both of these treatments.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME